Literature DB >> 12737879

Diabetic foot ulcers.

William J Jeffcoate1, Keith G Harding.   

Abstract

Ulceration of the foot in diabetes is common and disabling and frequently leads to amputation of the leg. Mortality is high and healed ulcers often recur. The pathogenesis of foot ulceration is complex, clinical presentation variable, and management requires early expert assessment. Interventions should be directed at infection, peripheral ischaemia, and abnormal pressure loading caused by peripheral neuropathy and limited joint mobility. Despite treatment, ulcers readily become chronic wounds. Diabetic foot ulcers have been neglected in health-care research and planning, and clinical practice is based more on opinion than scientific fact. Furthermore, the pathological processes are poorly understood and poorly taught and communication between the many specialties involved is disjointed and insensitive to the needs of patients.

Entities:  

Mesh:

Year:  2003        PMID: 12737879     DOI: 10.1016/S0140-6736(03)13169-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  183 in total

1.  Protein tyrosine phosphatase 1B impairs diabetic wound healing through vascular endothelial growth factor receptor 2 dephosphorylation.

Authors:  Jing Zhang; Limin Li; Jing Li; Yuan Liu; Chen-Yu Zhang; Yujing Zhang; Ke Zen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-11-13       Impact factor: 8.311

2.  [Diffusion of ulcers in the diabetic foot is promoted by stiffening of plantar muscular tissue under excessive bone compression].

Authors:  A Gefen; E Linder-Ganz
Journal:  Orthopade       Date:  2004-09       Impact factor: 1.087

3.  Receipt of care and reduction of lower extremity amputations in a nationally representative sample of U.S. Elderly.

Authors:  Frank A Sloan; Mark N Feinglos; Daniel S Grossman
Journal:  Health Serv Res       Date:  2010-08-16       Impact factor: 3.402

4.  Mepenzolate bromide promotes diabetic wound healing by modulating inflammation and oxidative stress.

Authors:  Yongjun Zheng; Xingtong Wang; Shizhao Ji; Song Tian; Haibin Wu; Pengfei Luo; He Fang; Li Wang; Guosheng Wu; Shichu Xiao; Zhaofan Xia
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

Review 5.  Surgical revascularization techniques for diabetic foot.

Authors:  Siva Krishna Kota; Sunil Kumar Kota; Lalit Kumar Meher; Satyajit Sahoo; Sudeep Mohapatra; Kirtikumar Dharmsibhai Modi
Journal:  J Cardiovasc Dis Res       Date:  2013-06-18

6.  Allogeneic keratinocyte for intractable chronic diabetic foot ulcers: A prospective observational study.

Authors:  Yeok G Hwang; Jin W Lee; Kwang H Park; Seung H Han
Journal:  Int Wound J       Date:  2019-01-02       Impact factor: 3.315

7.  Sonoporation of the minicircle-VEGF(165) for wound healing of diabetic mice.

Authors:  C S Yoon; H S Jung; M J Kwon; S H Lee; C W Kim; M K Kim; M Lee; J H Park
Journal:  Pharm Res       Date:  2008-11-08       Impact factor: 4.200

8.  Biomolecular signatures of diabetic wound healing by structural mass spectrometry.

Authors:  Kelly M Hines; Samir Ashfaq; Jeffrey M Davidson; Susan R Opalenik; John P Wikswo; John A McLean
Journal:  Anal Chem       Date:  2013-03-21       Impact factor: 6.986

9.  Neurotrophin p75 receptor (p75NTR) promotes endothelial cell apoptosis and inhibits angiogenesis: implications for diabetes-induced impaired neovascularization in ischemic limb muscles.

Authors:  Andrea Caporali; Elisabetta Pani; Anton J G Horrevoets; Nicolle Kraenkel; Atsuhiko Oikawa; Graciela B Sala-Newby; Marco Meloni; Brunella Cristofaro; Gallia Graiani; Aurelie S Leroyer; Chantal M Boulanger; Gaia Spinetti; Sung Ok Yoon; Paolo Madeddu; Costanza Emanueli
Journal:  Circ Res       Date:  2008-06-19       Impact factor: 17.367

10.  Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK.

Authors:  Jeroen P Jansen; Ritesh Kumar; Yehuda Carmeli
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.